Thetis Pharmaceuticals
PrivateLast Round
Debt
Jan 9, 2025
Total Funding Raised
$17.4M
Company Overview
Thetis Pharmaceuticals is a clinical-stage pharmaceutical company that develops first-in-class oral Resolvin E1 therapeutics for inflammatory bowel disease and solid tumors.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Thetis Pharmaceuticals Comparables
Compare Thetis Pharmaceuticals with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Landos Biopharma | 77% | |
| Theravance Biopharma Inc | 72% | |
| Surrozen | 69% | |
Thetis Pharmaceuticals Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Debt | Jan 9, 2025 | ||||
| Debt | Apr 4, 2022 | ||||
| Grant | Jul 12, 2021 | ||||
| Grant | Nov 19, 2019 | ||||
| Grant | Aug 1, 2018 | ||||
Grant | Nov 16, 2017 |
Key People
Founding team and executive leadership
Thetis Pharmaceuticals Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Connecticut Innovations | Seed |
| NIH RADx | Grant |
| Helmsley Charitable Trust | Debt |
| National Institute of Diabetes and Digestive and Kidney Diseases | Grant |
| Stonehenge Growth Capital | Seed |
| Crohn's & Colitis Foundation | Grant |
| Kenneth Rainin Foundation | Grant |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jul 12, 2021
$350K grant from Kenneth Rainin Foundation
- Aug 1, 2018
Received grant from Kenneth Rainin Foundation.
Thetis Pharmaceuticals Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about Thetis Pharmaceuticals's valuation, stock price, and market status.